Kazuharu Kamachi

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 9

Top Topics

Acute Myeloid Leukemia

Advanced Non Small Cell Lung Cancer

Tyrosine Kinase

Cell Proliferation

Top Venues

Cancer research communications

International cancer conference journal

This page only lists publications with an associated author ORCID identifier.

Publications

Tatsuro Watanabe, Yuta Yamamoto, Yuki Kurahashi, Kazunori Kawazoe, Keisuke Kidoguch, Hiroshi Ureshino, Kazuharu Kamachi, Nao Yoshida-Sakai, Yuki Fukuda-Kurahashi, Hideaki Nakamura, Seiji Okada, Eisaburo Sueoka, Shinya Kimura
Reprogramming of pyrimidine nucleotide metabolism supports vigorous cell proliferation of normal and malignant T cells. Blood advances (2024)
Tatsuro Watanabe, Yuta Yamamoto, Yuki Kurahashi, Kazunori Kawazoe, Keisuke Kidoguch, Hiroshi Ureshino, Kazuharu Kamachi, Nao Yoshida-Sakai, Yuki Fukuda-Kurahashi, Hideaki Nakamura, Seiji Okada, Eisaburo Sueoka, Shinya Kimura
Reprogramming of pyrimidine nucleotide metabolism supports vigorous cell proliferation of normal and malignant T cells. Blood advances 8 (6) (2024)
Tatsuro Watanabe, Yuta Yamamoto, Yuki Kurahashi, Kazunori Kawazoe, Keisuke Kidoguch, Hiroshi Ureshino, Kazuharu Kamachi, Nao Yoshida-Sakai, Yuki Fukuda-Kurahashi, Hideaki Nakamura, Seiji Okada, Eisaburo Sueoka, Shinya Kimura
Reprogramming of pyrimidine nucleotide metabolism supports vigorous cell proliferation of normal and malignant T cells. Blood advances 8 (6) (2024)
Kazunori Kawasoe, Tatsuro Watanabe, Nao Yoshida-Sakai, Yuta Yamamoto, Yuki Kurahashi, Keisuke Kidoguchi, Hiroshi Ureshino, Kazuharu Kamachi, Yuki Fukuda-Kurahashi, Shinya Kimura
A Combination of Alectinib and DNA-Demethylating Agents Synergistically Inhibits Anaplastic-Lymphoma-Kinase-Positive Anaplastic Large-Cell Lymphoma Cell Proliferation. Cancers 15 (20) (2023)
Kazuharu Kamachi, Hiroshi Ureshino, Tatsuro Watanabe, Nao Yoshida-Sakai, Yuki Fukuda-Kurahashi, Kazunori Kawazoe, Toshimi Hoshiko, Yuta Yamamoto, Yuki Kurahashi, Shinya Kimura
Combination of a New Oral Demethylating Agent, OR2100, and Venetoclax for Treatment of Acute Myeloid Leukemia. Cancer research communications 3 (2) (2023)
Kazuharu Kamachi, Hiroshi Ureshino, Tatsuro Watanabe, Nao Yoshida-Sakai, Yuki Fukuda-Kurahashi, Kazunori Kawazoe, Toshimi Hoshiko, Yuta Yamamoto, Yuki Kurahashi, Shinya Kimura
Combination of a New Oral Demethylating Agent, OR2100, and Venetoclax for Treatment of Acute Myeloid Leukemia. Cancer research communications 3 (2) (2023)
Hiroshi Ureshino, Kazuharu Kamachi, Haruhiko Sano, Sho Okamoto, Hidekazu Itamura, Mariko Yoshimura, Hiroo Katsuya, Toshihiko Ando, Shinya Kimura
Higher neutrophil counts are associated with successful tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia. Hematology (Amsterdam, Netherlands) 27 (1) (2022)
Toshiaki Nagaie, Kazuharu Kamachi, Hiroaki Kitamura, Hiroshi Ureshino, Michiaki Akashi, Kazushige Nishimura, Hiroyuki Meiri, Shinya Kimura, Masaharu Miyahara
Eosinophilic cystitis mimicking hemorrhagic cystitis in relapsed follicular lymphoma. International cancer conference journal 11 (4) (2022)
Hiroshi Ureshino, Kazuharu Kamachi, Atsujiro Nishioka, Sho Okamoto, Hiroo Katsuya, Mariko Yoshimura, Yasushi Kubota, Toshihiko Ando, Shinya Kimura
Subsequent attempt tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia; a single institute experience. Hematological oncology 39 (4) (2021)